PMPriti Meena

Priti Meena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Priti Meena has a total of 185 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Oncohypertension: Unraveling the Link Between Cancer and Hypertension

    by Prakash Gudsoorkar, Paul E. Hanna, Priti Meena, Sabine Karam

  • Open Access

    Electrolyte homeostasis in pregnancy: from physiological adaptations to clinical disturbances — a nephrologist’s perspective

    by Priti Meena, Aisha Batool

    Electrolyte homeostasis in pregnancy undergoes several important remodellings driven by systemic vasodilation, activation of neurohormonal pathways, increased glomerular filtration, altered tubular transport, and active maternal–fetal mineral exchange. These coordinated adaptations enable plasma volume expansion, mainta in utero placental perfusion, and support fetal growth, yet they narrow compensatory reserves and shift normal biochemical reference thresholds. As a result, reliance on non-pregnant laboratory norms can misclassify abnormalities, delaying recognition of clinically important disturbances. Understanding pregnancy-specific physiology is therefore essential for accurate diagnosis, monitoring, and therapeutic decision-making. This review provides an integrated nephrology-focused synthesis of normal adaptive mechanisms and disorder-specific pathophysiology across sodium–water, potassium, magnesium, and calcium balance. We summarize expected gestational changes, including the reset osmostat and AVP-mediated free-water retention causing a physiological fall in serum sodium, changes in potassium homeostasis and magnesium homeostasis, and the doubling of intestinal calcium absorption driven by increased calcitriol to meet third-trimester skeletal mineralization. We further review common clinical disorders of water and sodium, potassium, calcium, and magnesium. The review provides a comprehensive pregnancy-specific interpretation of electrolyte values, diagnostic evaluation strategies, and targeted management tailored to maternal and fetal safety aimed at improving clinical vigilance and optimizing outcomes.


  • Open Access

    A multicenter prospective real-world cohort study of direct oral anticoagulant use for venous thromboembolism prophylaxis in nephrotic syndrome

    by Priti Meena, Nitin Kumar, Sandip Kumar Panda, Sharon Kandari, Ganesh Srinivasa Prasad, Vinant Bhargava, Vikash Khandelia, Prashant Malviya, Nikunj Kishore Rout, Paromita Das, et al.

    Nephrotic syndrome (NS), especially when associated with severe hypoalbuminia, confers a high risk of venous thromboembolism (VTE). While low-molecular-wei

  • Parvovirus B19 Infection in Kidney Transplant Recipients: Clinical Spectrum, Management, and Outcomes in a Large Multicentered Indian Cohort

    by Priti Meena, Vijaychander Bukka, Vinant Bhargava, Vivek Pathak, Umapati Hegde, Vishal Singh, Ashay Shingare, Sanjiv Jasuja, Vishwanath Siddini, Swarnalatha Guditi, et al.

    Background: Parvovirus B19 (PVB19) is a clinically important cause of refractory anemia in kidney transplant recipients (KTRs). Data from low‐ and middle‐income settings remain scarce despite high transplant volumes. This study evaluated the clinical spectrum, management practices, and outcomes of PVB19 infection across major transplant programs in India. Methods: We conducted a retrospective multicenter cohort study across 14 tertiary transplant centers. All KTRs with PCR‐confirmed PVB19 infection and complete clinical data were included. Clinical features, bone marrow findings, immunosuppressive (IS) adjustments, intravenous immunoglobulin (IVIG) use, and patient and graft outcomes were analyzed. Results: A total of 135 KTRs were identified. Median time to infection was 11 weeks posttransplant. Anemia was universal, not frequently accompanied by leukopenia (17.7%) or thrombocytopenia (14.8%). Bone marrow examinations ( n = 34) demonstrated giant proerythroblasts or pure red cell aplasia. IS reduction was implemented in all patients; most commonly, complete MMF withdrawal (61.5%). IVIG was administered to 90% (median cumulative dose 100 g). Overall, 97% achieved hematologic recovery, with a median response time of 20 days. Recurrence occurred in 4.4%. At a median follow‐up of 18 months, graft survival was 92.6%; graft loss ( n = 10) was primarily due to antibody‐mediated rejection, and no deaths were attributable to PVB19. Conclusions: PVB19 infection represents an important consideration in the differential diagnosis of early posttransplant anemia in KTRs. Timely PCR testing and pragmatic treatment strategies can achieve favorable hematologic and graft outcomes in resource‐constrained settings.


  • Open Access

    A Multicentric prospective Real-World Experience of Direct Oral Anticoagulants use in prophylaxis of Venous Thromboembolism in Nephrotic syndrome

    by Priti Meena, Nitin Kumar, Sandip Kumar Panda, Sharon Kandari, Ganesh Srinivasa Prasad, Vinant Bhargava, Vikash Khandelia, Prashant Malviya, Nikunj Kishore Rout, Paromita Das, et al.

    Introduction : Patients with nephrotic syndrome (NS), particularly with severe hypoalbuminia are at significantly increased risk for venous thromboembolism (VTE). Although vitamin K antagonists (VKAs) have traditionally been used for prophylaxis. Evidence supporting direct oral anticoagulants (DOACs) for primary prophylaxis in NS remains scarce, with a lack of prospective real-world data. Methods : We conducted a prospective multicentric cohort study across eight tertiary centers in India, enrolling adults (≥ 18 years) with NS and severe hypoalbuminemia (albumin < 2.4 g/dL for Membranous nephropathy; <2.0 g/dL for other etiologies). All patients received apixaban 5 mg once daily as primary VTE prophylaxis until albumin levels improved beyond 2.4 g/dL. The primary composite outcome included VTE occurrence and major or clinically significant bleeding events. Patients were followed until anticoagulation discontinuation. Results : A total of 212 patients were analyzed (mean age 36.9 ± 14.0 years, 52% male). Median proteinuria was 9.0 g/day and mean serum albumin 1.68 ± 0.49 g/dL; mean serum creatinine was 1.5 ± 0.54 mg/dL. Most patients were categorized as low (80%) or intermediate (20%) bleeding risk by GN tool. Membranous nephropathy was the most common etiology (45%). Immunosuppressive therapy included corticosteroids (81%), rituximab (25.9%), and cyclophosphamide (28.3%). The mean duration of apixaban therapy was 3 months. No venous or arterial thromboembolic events occurred, and minor bleeding was observed in 4 patients (3.5%), all resolving without transfusion or hospitalization. Overall apixaban was well tolerated. Conclusion : This large multicenter prospective study showed that apixaban prophylaxis appears safe, well-tolerated, and potentially effective in preventing VTE among high-risk NS patients. Larger randomized trials are needed to validate findings and optimize dosing, but current data support the rational integration of DOACs into NS thromboprophylaxis protocols.

  • Open Access

    Clinical Profile and Outcomes of Acute Kidney Injury Associated with Scrub Typhus Infection: A Systematic Review

    by Priti Meena, Scienthia Sanjeevani, Badari Mylliemngap, Prity Kumari Rai, Sandip Panda, Vr Krishnakumar

    Background: AKI remains a significant global health burden, with infectious etiologies predominant in tropical regions. Among these, scrub typhus, caused by Orientia tsutsugamushi , has emerged as a critical cause, particularly in endemic areas. Kidney involvement in scrub typhus varies widely, ranging from mild abnormalities to severe renal failure requiring dialysis. Materials and Methods: A systematic review was conducted by searching PubMed/MEDLINE, EMBASE, and Cochrane CENTRAL databases for studies published between January 2000 and December 2024 on scrub typhus-associated AKI. Extracted data included demographics, clinical characteristics, AKI details, dialysis requirements, and long-term outcomes. Results: Of the 1,969 records retrieved, 14 studies comprising 4,290 scrub typhus patients were included, with 1,094 (28.7%) developing AKI. The studies, conducted in India, Nepal, and South Korea, reported an AKI incidence of 13.16% to 53%. Diagnosis was based on RIFLE and KDIGO criteria in seven and six studies, respectively. AKI predominantly affected males (48-77.1%), with ages ranging from 30-71 years. Fever (94-100%) was universal, while eschar was more frequent in Korean studies. Key AKI predictors included older age, pre-existing CKD, hypoalbuminemia, and multi-organ dysfunction syndrome. Mortality ranged from 0.7% to 35.7%. Dialysis requirement varied (0.21-46.7%), but no study reported dialysis dependency at follow-up. Most patients recovered renal function within 3 months, though 1-2% had persistent dysfunction. Conclusion: Scrub typhus-associated AKI is a significant complication with high morbidity and mortality. Early identification of risk factors and timely intervention can improve renal and patient outcomes.


  • Open Access

    Clinicopathological Features and Outcomes of Fibrillary Glomerulonephritis in an Indian Cohort: A Multicentric Study

    by Priti Meena, Anila Kurien, Raja Ramachandran, Mahesha Vankalakunti, Vinant Bhargava, Manisha Sahay, Vishwanath Siddini, Pallav Gupta, Atanu Pal, Prit Pal Singh, et al.


  • Open Access

    Global Inequities in Pregnancy in Women With Kidney Disease

    by Priti Meena, Rasha Shemies, Prasoon Verma, Silvi Shah


  • Open Access

    Pregnancy-associated acute kidney injury as an important driver of chronic kidney disease in females in developing countries: A systematic review

    by Priti Meena, Paromita Das, Anagha Auradkar, Adel Moideen, Vinant Bhargava, Umang Kasturi, Vidhi Singla, Sandip Panda, Krithika Mohan

    Pregnancy-related AKI (PR-AKI), has profound maternal and fetal implications, including high mortality and long-term risks such as the development of chronic kidney disease (CKD). This systematic review aims to evaluate the burden of CKD owing to PR-AKI cases during follow-up in developing countries, particularly India. A systematic search of PubMed, Embase, and Cochrane databases was performed for Indian studies published between 2000 and June 2024. We included cross-sectional, retrospective, and prospective cohort studies that reported the incidence of PR-AKI, subsequent CKD, and dialysis dependency in Indian cohorts during follow-up. Details of etiology of PRAKI, and adverse fetal and maternal outcomes were also recorded. Only studies that provided follow-up kidney outcomes were considered. A total of 25 studies comprising 2,306 participants were included in the analysis. The incidence of PR-AKI ranged from 1 to 12% across different studies. Sepsis was the most common cause of PR-AKI, accounting for up to 78% of cases, followed by hypertensive disorders, obstetric haemorrhage, and tropical etiologies. Hemodialysis was required in 20–85% of patients. CKD development during follow-up was observed in 12.8–35% of cases, with up to 30% remaining dialysis-dependent. Maternal mortality ranged from 2.5 to 34%, while perinatal mortality reached as high as 67.3%. Pre-term delivery rates varied between 13.9% and 58%. Up to one-third of PR-AKI patients may develop CKD and remain dialysis-dependent during follow-up. PR-AKI significantly impacts both maternal and fetal morbidity and mortality. Early prevention and prompt management by healthcare professionals are critical to improving outcomes in PR-AKI. Pregnancy-related acute kidney injury (PR-AKI) significantly affects maternal and fetal health, leading to high mortality and long-term complications such as chronic kidney disease (CKD). This systematic review, focusing on developing countries like India, evaluated the burden of CKD due to PR-AKI patients. The review analyzed Indian studies published between 2000 and June 2024, including 25 studies with 2,306 participants. PR-AKI incidence ranged from 1 to 12%, with sepsis being the leading cause in up to 78% of cases, followed by hypertensive disorders, obstetric hemorrhage, and tropical fevers. RRT was needed in 20–85% of patients, and 12.8–35% developed CKD during follow-up, with up to 30% remaining dialysis-dependent. Maternal mortality varied from 2.5 to 34%, while perinatal mortality reached 67.3%. The study emphasizes the critical need for early prevention timely intervention and need for long-term follow-up to reduce the high morbidity and mortality rates associated with PR-AKI.